No profile data available.
Enanta Pharmaceuticals, Inc. (ENTA) is a healthcare company in the hepatic treatment pharmaceuticals industry, based in Watertown, United States, with about 120 full-time employees.
It reported revenue of $65.32 million for fiscal year 2025, down 3.4% from fiscal year 2024, and net income of -$81.89 million. In Q3 2026 (the quarter ended June 30, 2026) revenue was $14.36 million, down 21.6% from a year before. Its market capitalization was $364.07 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended September 30, 2025; market data as of October 9, 2026.
, a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.
Enanta Pharmaceuticals reported $65.32 million in revenue for fiscal year 2025, down 3.4% from $67.64 million in fiscal year 2024. In Q3 2026 revenue was $14.36 million.
$364.07 million as of October 9, 2026.
Listed companies of a similar size in the same industry (hepatic treatment pharmaceuticals) include Sagimet Biosciences Inc. (SGMT), Monopar Therapeutics Inc. (MNPR), Galectin Therapeutics Inc. (GALT), Precision BioSciences, Inc. (DTIL).